BRIEF published on 06/14/2024 at 22:50, 5 months 7 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 5 months 7 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 5 months 9 days ago Rutherrin® augmente l'efficacité de la chimiothérapie Traitement Du Cancer Chimiothérapie Rutherrin® Résistance Multidrogue Technologies Theralase®
BRIEF published on 06/12/2024 at 13:05, 5 months 9 days ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 5 months 9 days ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 5 months 11 days ago Ruvidar(TM) améliore l'efficacité d'un médicament contre le cancer Traitement Du Cancer Technologies Théralase Ruvidar(TM) BCG NMIBC
BRIEF published on 06/10/2024 at 13:05, 5 months 11 days ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 5 months 11 days ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 5 months 15 days ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
BRIEF published on 06/06/2024 at 13:05, 5 months 15 days ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
Published on 11/22/2024 at 00:00, 1 hour 52 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 3 hours 47 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 4 hours 2 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 5 hours 37 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 5 hours 42 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 19:01, 6 hours 50 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 7 hours 16 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 7 hours 53 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 8 hours ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 8 hours ago LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Published on 11/21/2024 at 06:58, 18 hours 54 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 18 hours 54 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 18 hours 54 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 5 hours ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 6 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
